

CPNP 2021 HIGHLIGHTS



Live Sessions

Log on, submit questions, and learn alongside your peers tuning in across the country as 18 impactful sessions are presented live over the 5 days of CPNP 2021!



Watch Parties

Enjoy the convenience of learning on your schedule through watch-parties featuring extra, on-demand programming at no additional charge. As an added bonus, sessions approved for BCPP Recertification credit will be offered both live and via a watch party with speakers answering your questions in real-time.



Industry Educational Events

Benefit from up to 5 industry provided educational programs offering medication use and disease state insights. Be sure to add these sessions to your CPNP 2021 schedule.



Networking

Network and engage with your colleagues through activities such as a daily networking hour, team trivia competition, 2 poster sessions, and more!

Early Bird Registration Fees

(Available through 4/1/21 – see cpnp.org/register)

	Member	Non-member
Pharmacist Registration	\$350	\$450
Fellow/Resident Registration	\$210	\$295
Student Registration	\$95	\$150

FEATURED SESSIONS & SPEAKERS



Antidepressants for Bipolar: Pro-Con-Debate Monday, April 19 • 9:00 AM Central

Joseph F. Goldberg, MD, Clinical Professor of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, and Andrew Nierenberg, MD, Director of Dauten Family Center for Bipolar Treatment Innovation, Boston, MA



There are many nuances to consider when evaluating the risks and benefits of antidepressant use in bipolar disorder (BD). Short-term efficacy of antidepressants for BD remains controversial and risks clinical worsening, especially in mixed states and with rapid-cycling. In this session, Drs. Goldberg and Nierenberg will debate the pros and cons of antidepressant use for BD treatment. You will hear evidence on both sides of the debate and gain insight to better make future treatment recommendations.



A Hidden Crisis: Understanding Adverse Childhood Experiences, Trauma, and Impacts on Development Wednesday, April 21 • 9:00 AM Central

Katherine A. Lingras, PhD, LP, Assistant Professor and Child Psychologist, University of Minnesota – Department of Psychiatry and Behavioral Sciences, Minneapolis, MN

Adverse Childhood Experiences (ACEs) are associated with medical, social, and public health problems. ACEs are associated with 7 out of the top 10 chronic disease states, and those with high exposure to ACEs have a 20-year difference in life-expectancy. While screening for ACEs is recommended, its practice is still limited. Additional education is needed to increase awareness of ACEs as well as the strategies that may be employed to prevent them. You will learn how to identify and screen for ACEs and the mechanisms by which ACEs may affect the development of psychopathology and chronic illness.



Immediate and Long-Term Consequences of SARS-CoV-2 infection: A Global Exploration Wednesday, April 21 • 10:15 AM Central

Sudha Seshadri, MD, Professor and Director, Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, TX

Scientific leaders, including the Alzheimer's Association and representatives from more than 25 countries, are working together with technical guidance from the World Health Organization (WHO) to track the long-term impact of SARS-CoV-2 (COVID-19) on the brain. Although little is known about the long-term consequences of SARS-CoV-2 infection, there are several research studies to suggest that COVID-19 is associated with neurological complications. In this session, you will learn about ongoing research into the long-term consequences that may impact the brain, cognition, and function.



Evaluating Psychotropic Drug Safety in Breastfeeding Thursday, April 22 • 9:00 AM Central

Thomas W. Hale, RPh, PhD, University Distinguished Professor, Director, Clinical Research Unit, Director InfantRisk Center, Texas Tech University School of Medicine, Amarillo, TX

With so many women using drug therapy during lactation, pediatricians and obstetricians are faced with the challenge of determining which medications are suitable for breastfeeding mothers. Although there is more literature available about the transfer of medications into breast milk, this is often not communicated to students and clinicians; therefore, many women are advised to stop breastfeeding or avoid drug therapy based on information obtained from product monographs. Learn how medications enter breast milk to aid in clinical decisions and highlight suitable medications for breastfeeding mothers.

CPNP 2021 PROGRAMMING

BCPP Recertification Sessions* (ACPE and BCPP Recertification Credit) 	
Antipsychotic Adverse Effects Comparison	Stephen R. Saklad, PharmD, BCPP , Clinical Professor and Director of Psychiatric Pharmacy, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division and Adjoint Professor of Medicine, University of Texas Health San Antonio, San Antonio, TX
Harm Reduction Strategies in Opioid Use Disorder	Michelle Geier, PharmD, BCPP, Aph , Psychiatric Clinical Pharmacist Supervisor, San Francisco Department of Public Health, San Francisco, CA
Management of Acute Repetitive Seizures	Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS , Professor of Pharmacotherapy & Outcomes Science and Neurosurgery, Virginia Commonwealth University School of Pharmacy, Richmond, VA
Pharmacologic Management of Insomnia with Sleep Apnea	Elayne D. Ansara, PharmD, BCPS, BCPP , Clinical Pharmacy Specialist – Mental Health, Veteran Health Indiana, Indianapolis, IN
Role of Newer Antidepressants in Social Anxiety Disorder (SAD)	Sarah T. Melton, PharmD, BCPP, BCACP, FASCP , Professor of Pharmacy Practice, Gatton College of Pharmacy at East Tennessee State University, Johnson City, TN
Live Sessions	
Dual Diagnosis: Managing the Complex Patient with Depression and AUD	Dana Chiulli, PharmD, BCPP , Mental Health Clinical Pharmacy Specialist, Ralph H Johnson VA, Savannah, GA
Gastric Bypass: Management of Psychotropic Medications Following Bariatric Surgery	April Smith, PharmD, MA, BCPS , Associate Professor of Pharmacy Practice, Creighton University, Omaha, NE
Older Medication Pearls	Rex Lott, PharmD, BCPP , Professor Emeritus, Idaho State University College of Pharmacy, Meridian, ID Cynthia K. Kirkwood, PharmD, BCPP , Professor, Executive Associate Dean for Academic Affairs, Virginia Commonwealth University School of Pharmacy, Richmond, VA M. Lynn Crismon, PharmD, FCCP, DABCP, BCPP , Behrens Centennial Professor of Pharmacy, College of Pharmacy, and Professor of Psychiatry, Dell Medical School, The University of Texas at Austin, Austin, TX
Parkinson's Disease: New Pharmacologic Tools in the Management of Motor Fluctuation	Daniel O. Claassen, MD, MS , Associate Professor of Neurology, Vanderbilt University Medical Center, Nashville, TN
Psychiatric and Neurologic Medication Pipeline	Stephen R. Saklad, PharmD, BCPP , Clinical Professor and Director of Psychiatric Pharmacy, The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division and Adjoint Professor of Medicine, University of Texas Health San Antonio, San Antonio, TX
Sedative-Hypnotics: Benefits and Risks	Nicole Brandt, PharmD, MBA, BCGP, BCPP, FASCP , Executive Director and Professor, The Peter Lamy Center on Drug Therapy and Aging, University of Maryland, Baltimore, MD
Stimulant Treatment for ADHD in Complex Cases	Julie A. Dopheide, PharmD, BCPP, FASHP , Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, University of Southern California School of Pharmacy, Los Angeles, CA
Taking Antipsychotics to the Next Level: Evaluating Opportunities for Therapeutic Drug Monitoring	Kara Wong, PharmD, BCPP , Clinical Pharmacy Specialist, Mental Health; PGY-2 Psychiatric Pharmacy Residency Program Director. Minneapolis VA Health Care System, Minneapolis, MN
On Demand Sessions	
Non-Antipsychotics for Treatment Resistant Schizophrenia	Peter F. Buckley, MD , Dean, Virginia Commonwealth University School of Medicine, Richmond, VA
PTSD Management Among Civilian Populations	Arash Javanbakht, MD , Associate Professor, Wayne State University, Detroit, MI
The Role of Pharmacists in Medical Cannabis	Leah Sera, PharmD, MA, BCPS , Associate Professor and Director, Medical Cannabis Science and Therapeutics, University of Maryland School of Pharmacy, Rockville, MD
Transplant and Associated Mental Health	Paula Zimbrea, MD, FACLP, FAPA , Associate Professor of Psychiatry and Surgery (Transplant), Yale University School of Medicine; Director Transplant Psychiatry Services, Yale Transplant Center, New Haven, CT
Traumatic Brain Injury: A Focus on Long-term Neurologic Sequelae	Sunita Dergalust, PharmD, BCPS , Clinical Pharmacy Specialist in Neurology and Neurosurgery, VA Greater Los Angeles Healthcare System, Los Angeles, CA Viet Nguyen, PharmD, MPH, MSc , Assistant Professor, Chapman University and Faculty- in-Residence, Harbor UCLA Medical Center, Orange, CA

*BCPP Recertification Sessions are open to all CPNP 2021 attendees for ACPE credit, but an additional registration is required to earn BCPP Recertification credit.

Unless otherwise noted, sessions are ACPE approved and provide 1 contact hour of knowledge- or application-level programming.



The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2021 Annual Meeting will provide up to 23 contact hours of knowledge-based and application-based continuing education credit from CPNP approved programming. Industry supported symposia offered at the Annual Meeting offer additional ACPE credit.

Pre-Meeting Workshop

Wednesday, February 24 • 1:00-4:45 PM Central

Applying Pharmacogenomics (PGx) to Clinical Practice

ACPE Credit: 3.25 contact hours

There has been significant growth in the use of pharmacogenomics (PGx) testing applied to the prescribing of psychiatric medications. With the advent of direct to consumer testing options, providers may also be uncertain of what to do when presented with a testing result, especially when they may not understand the evidence behind the results. This program will be geared toward those with limited experience with PGx testing with the goal being to build and enhance pharmacists' understanding of the current state of evidence for incorporating pharmacogenomics into patient care plans. Join speakers **Jeff Bishop, PharmD, MS, BCPP** and **Vicki L. Ellingrod, PharmD, FCCP** for this hands-on workshop!

Register today!

Engagement and Networking Opportunities

Learn more at cpnp.org/2021



Idea Exchanges



Poster Sessions



Speed Networking



Daily Debriefs



Watch Parties



Trivia Night
Socializing

sponsored by the
CPNP Foundation

Registration to CPNP 2021 is available at cpnp.org/register

NONPROFIT ORG
US POSTAGE
PAID
OMAHA, NE
PERMIT NO. 498

College of Psychiatric
& Neurologic Pharmacists



8055 O Street, Ste. S113
Lincoln, NE 68510

Attend the
Premier Virtual
Conference on
Psychopharmacology!

APRIL 19-23, 2021

Goals and Target Audience

The CPNP Annual Meeting is designed to bridge the perceived practice and knowledge gap between current knowledge and practice in a number of areas of psychiatric, neurologic, and addiction pharmacy practice. Published evidence-based guidelines help establish standards in regard to medications, dosing, and treatment, however, there are often disparities seen in clinical practice when compared to these guidelines. Additionally, many guidelines fail to keep up with emerging treatments and controversial issues or simply do not address practical day-to-day treatment dilemmas. This meeting will bridge this gap in treatment and knowledge with selected psychiatric, neurologic, and substance use disorder issues.



Visit cpnp.org/2021 for more information



College of Psychiatric
& Neurologic Pharmacists

CPNP 2021

WHERE PHARMACY & PSYCHIATRY MEET

VIRTUAL ANNUAL MEETING

APRIL 19-23 • [CPNP.ORG/2021](https://cpnp.org/2021)